<DOC>
	<DOCNO>NCT02112851</DOCNO>
	<brief_summary>Randomized , placebo control , double blind , postprandial crossover study male subject . 3 intervention arm , consist control ( Product A ) , low dose process whole orange ( Product B ) high dose process whole orange ( Product C ) , determine effect intervention primary endpoint postprandial glycemia . Secondarily , plasma insulin concentration quantify .</brief_summary>
	<brief_title>Processed Orange Glycemic Response</brief_title>
	<detailed_description>The study design randomize , placebo control , double-blind , crossover . This trial include 33 subject randomize receive product A , B C [ 240 mL ( 255 g ) ] . Subjects randomly assign one 6 sequence 3 intervention . After initial screen visit , subject visit Clinical Translational Research Center ( CTRC ) Tufts Translational Clinical Science Institute ( CTSI ) three separate occasion . Following intervention day two week wash period .</detailed_description>
	<criteria>Males ( due potential hormonal fluctuation female subject ) age 3065 BMI : 2529.9 kg/m2 Not diabetic [ diagnose fast glucose &gt; 7 mmol/L ( 126 mg/dL ) ] suffer endocrine disorder Not suffer myocardial infarction/stroke past 12 mo Not suffer renal bowel disease history choleostatic liver pancreatitis Not drug treatment hyperlipidaemia , hypertension , inflammation hypercoagulation No history alcohol misuse Not plan weight reduce regime Not take fish oil , fatty acid vitamin mineral supplement Non smoker Females Use medication know affect lipid metabolism , i.e. , hypolipidemic cholesterollowering agent ( e.g. , Pravastatin , Simuvustatin ) Use ( &gt; 2x/wk ) medication inflammation hypercoagulation Anticoagulants ( Warfarin ) Inflammation NSAID 's ( Tiaprofenic acid , Sulindac , Ibuprofen ) , Corticosteroids ( Betamethasone ) Regular use ( &gt; 2x/wk ) acidlowering medication , laxative antidiarrheal medication ( prescription overthecounter [ OTC ] ) Use medication know suspected influence blood pressure , include betaadrenergic blocking agent ( oral ocular ) ( e.g. , Sotalol , Bisoprolol ) , betaadrenergic drug , calcium channel block agent ( Amlodipine , Nicardipine ) , angiotensin convert enzyme ( ACE ) inhibitor ( Captopril , Cilazapril ) , angiotensin receptor block agent ( Valsartan ) , nitrate , diuretic ( Chlortalidone ) , venlafaxine sibutramine , decongestant chloroquine Systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 95 mmHg CVD include coronary artery disease , leave ventricular hypertrophy , congestive heart failure , cerebrovascular disease , stroke , peripheral vascular disease dysautonomia Gastrointestinal diseases condition medication influence gastrointestinal absorption include active peptic ulcer disease , treatment acidlowering drug inflammatory bowel disease Renal chronic kidney disease due condition , renovascular disease , history nephrolithiasis serum creatinine &gt; 1.5 mg/dL Endocrine disorder include diabetes [ fast blood glucose &gt; 7 mmol/L ( 126 mg/dL ) current pharmacologic treatment diabetes ] , untreated thyroid disease , adrenal disease , pheochromocytoma , parathyroid disease hyperuricemia Rheumatologic diseases include gout inflammatory arthritis Active treatment cancer type ( except basal cell carcinoma ) &lt; 1 Regular use oral steroid except topical OTC steroid Regular use dietary supplement contain vitamin , mineral , herbal plantbased preparation , fish oil supplement ( include cod liver oil ) homeopathic remedy . However , subject willing refrain use supplement 1 mo prior initial visit ( Visit 3 ) may consider eligible . Usual daily ethanol intake &gt; 2 drink ( 24 oz beer , 8 oz wine , 2 oz hard liquor ) Cigarette smoke and/or nicotine replacement use . However , subject stop use product 1 prior initial visit ( Visit 1 ) may consider eligible . Illicit drug use Infrequent ( &lt; 3/wk ) excessive ( &gt; 3/d ) number regular bowel movement Specific laboratory blood urine analysis parameter : Creatinine &gt; 1.5 mg/dL Electrolytes , calcium , phosphorous normal range ALT AST &gt; 1.5 nmol Total bilirubin normal range Triglycerides ≥300 mg/dL Fasting glucose ≥126 mg/dL CBC : HCT outside normal NEL reference range discretion study physician WBC , PLT outside normal NEL reference range Strict vegetarian Those plan weight reduce regime Unable consume study meal product Subjects large 5 kg weight loss last 3 month .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>